4//SEC Filing
Davidson Matt 4
Accession 0001209191-19-043586
CIK 0001660334other
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 7:57 PM ET
Size
11.5 KB
Accession
0001209191-19-043586
Insider Transaction Report
Form 4
Davidson Matt
10% Owner
Transactions
- Sale
Common Stock
2019-07-25$10.23/sh−975$9,974→ 2,612,165 total - Sale
Common Stock
2019-07-29$11.62/sh−8,551$99,363→ 2,601,712 total - Sale
Common Stock
2019-07-26$10.65/sh−1,902$20,256→ 2,610,263 total - Sale
Common Stock
2019-07-29$12.52/sh−630$7,888→ 2,601,082 total
Footnotes (5)
- [F1]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.29 to $10.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.13 to $12.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.34 to $12.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Verrica Pharmaceuticals Inc.
CIK 0001660334
Entity typeother
Related Parties
1- filerCIK 0001741937
Filing Metadata
- Form type
- 4
- Filed
- Jul 28, 8:00 PM ET
- Accepted
- Jul 29, 7:57 PM ET
- Size
- 11.5 KB